Trypanocidal effect of α′,β′-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity

International Journal of Antimicrobial Agents

Volumn 24, Issue 3, 2004, Pages 286-289

  Glenn, Robert J ^a   Pemberton, Alexander J ^a   Royle, Howard J ^a   Spackman, Robert W ^a   Smith, Emily ^a   Jennifer Rivett, A ^a   Steverding, Dietmar ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Epoxomicin; HL 60 cells; Proteasome; Sleeping sickness; Trypanosoma brucei; YU101

Indexed keywords

EPOXIDE; EPOXOMICIN; KETONE DERIVATIVE; N ACETYLHOMOPHENYLALANYLLEUCYLPHENYLALANYLLEUCYLMETHYLORIXANE; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; YU 101; ANTITRYPANOSOMAL AGENT; ENZYME INHIBITOR; OLIGOPEPTIDE; PROTEASOME; YU101;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ANALYSIS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA BRUCEI; ANIMAL; CELL CULTURE; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

TRYPANOSOMA BRUCEI;

ANIMALS; CELLS, CULTURED; ENZYME INHIBITORS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PARASITIC SENSITIVITY TESTS; PROTEASOME ENDOPEPTIDASE COMPLEX; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI;

EID: 4344593765     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2004.02.023     Document Type: Article

References (22)

1. WHO. African trypanosomiasis or sleeping sickness. World Health Org Fact Sheet 2001;259 (http://www.who.int/mediacentre/factsheets/fs259/en/print.html).
2. Burchmore R.J., Ogbunude P.O., Enanga B., Barrett M.P. Chemotherapy of human African trypanosomiasis. Curr. Pharm. Des. 8:2002;256-267
3. Matovu E., Seebeck T., Enyaru J.C.K., Kaminsky R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 3:2001;763-770
4. Nkemgu-Njinkeng J., Rosenkranz V., Wink M., Steverding D. Antitrypanosomal activities of proteasome inhibitors. Antimicrob Agents Chemother. 46:2002;2038-2040
5. Coux O., Tanaka K., Goldberg A.L. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 65:1996;801-847
6. Hua S.-B., To W.-Y., Nguyen T.T., Wong M.-L., Wang C.C. Purification and characterization of proteasomes from Trypanosoma brucei. Mol. Biochem. Parasitol. 78:1996;33-46
7. Wang C.C., Bozdech Z., Liu C.-l., et al. Biochemical analysis of the 20 S proteasome of Trypanosoma brucei. J. Biol. Chem. 278:2003;15800-15808
8. Groll M., Kim K.B., Kairies N., Huber R., Crews C.M. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α′,β′-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 122:2000;1237-1238
9. Hanada M., Sugawara K., Kaneta K., et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo). 45:1992;1746-1752
10. Elofsson M., Splittgerber U., Myung J., Mohan R., Crews C.M. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α′,β′-epoxyketones. Chem. Biol. 6:1999;811-822
11. Hirumi H., Hirumi K., Doyle J.J., Cross G.A.M. In vitro cloning of animal-infective bloodstream forms of Trypanosoma brucei. Parasitology. 80:1980;371-382
12. Baltz T., Baltz D., Giroud C., Crockett J. Cultivation in a semi-defined medium of animal infective forms of Trypanosoma brucei, T. equiperdum, T. evansi, T. rhodesiense and T. gambiense. EMBO J. 4:1985;1273-1277
13. Nkemngu N.J., Grande R., Hansell E., McKerrow J.H., Caffrey C.R., Steverding D. Improved trypanocidal activities of cathepsin L inhibitors. Int. J. Antimicrob. Agents. 22:2003;155-159
14. Merschjohann K., Sporer F., Steverding D., Wink M. In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. Planta Med. 67:2001;623-627
15. 50 in studies of drug resistance of malaria parasites. Acta Trop. 55:1993;257-261
16. Rivett A.J., Savory P.J., Djaballah H. Multicatalytic endopeptidase complex: proteasome. Meth Enzymol. 244:1994;331-350
17. Nazif T., Bogyo M. Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors. Proc. Natl. Acad. Sci. USA. 98:2001;2967-2972
18. Bogyo M., Shin S., McMaster J.S., Ploegh H.L. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5:1998;307-320
19. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov. Today. 8:2003;307-315
20. Meng L., Mohan R., Kwok B.H.B., Elofsson M., Sin N., Crews C.M. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA. 96:1999;10403-10408
21. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 59:1999;2615-2622
22. Millennium Pharmaceuticals, Inc., FDA approves VELCADE™ (bortezomib) for injection for the treatment of relapsed and refractory multiple myeloma. Millennium Media Press Releases 2003 (http://www.mlnm.com/media/news/ 2003/2003-05-13-0.asp).